Drug Profile
Pegaspargase biosimilar - Gennova Biopharmaceuticals
Alternative Names: HamsylLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Gennova Biopharmaceuticals
- Developer Emcure Pharmaceuticals; Gennova Biopharmaceuticals
- Class Amidohydrolases; Antineoplastics; Polyethylene glycols
- Mechanism of Action Aspartate-ammonia ligase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 26 Mar 2019 Gennova Biopharmaceuticals completes a phase II trial in Precursor cell lymphoblastic leukaemia-lymphoma (In children, In adolescents) in India (IM) (CTRI/2016/02/006589)
- 01 Feb 2016 Preclinical trials in Acute lymphoblastic leukaemia (Second-line therapy or greater, In children) in India (IM) before February 2016 (CTRI/2016/02/006589)
- 01 Feb 2016 Gennova Biopharmaceuticals plans a clinical trial for Acute lymphoblastic leukaemia (In children) in India (CTRI/2016/02/006589)